Review



bk036  (Cytoskeleton Inc)


Bioz Verified Symbol Cytoskeleton Inc is a verified supplier
Bioz Manufacturer Symbol Cytoskeleton Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Cytoskeleton Inc bk036

    Bk036, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 95/100, based on 268 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bk036+rac1/pmc05768420-27-16-10?v=Cytoskeleton+Inc
    Average 95 stars, based on 268 article reviews
    bk036 - by Bioz Stars, 2026-07
    95/100 stars

    Images

    1) Product Images from "Paxillin facilitates timely neurite initiation on soft-substrate environments by interacting with the endocytic machinery"

    Article Title: Paxillin facilitates timely neurite initiation on soft-substrate environments by interacting with the endocytic machinery

    Journal: eLife

    doi: 10.7554/eLife.31101


    Figure Legend Snippet:

    Techniques Used: Recombinant



    Similar Products

    95
    Cytoskeleton Inc bk036

    Bk036, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bk036+rac1/pmc05768420-27-16-10?v=Cytoskeleton+Inc
    Average 95 stars, based on 1 article reviews
    bk036 - by Bioz Stars, 2026-07
    95/100 stars
      Buy from Supplier

    96
    Cytoskeleton Inc bk036 rac1

    Bk036 Rac1, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bk036+rac1/pm41984592-140-69-76?v=Cytoskeleton+Inc
    Average 96 stars, based on 1 article reviews
    bk036 rac1 - by Bioz Stars, 2026-07
    96/100 stars
      Buy from Supplier

    96
    Cytoskeleton Inc rac1
    Fig. 4 BRAFV600E acts during G1/S and activates <t>RAC1</t> to downregulate RhoA and generate tetraploid cells. A Fold change in G1 RPE-1 FUCCI tetraploids following inhibitor treatment. Fold changes are expressed relative to control (+BRAFV600E, no drug) samples. Inhibitors were added at indicated timepoints. N = 4 independent experiments. One-way ANOVA with Dunnett’s multiple comparisons test. Error bars represent mean ± SEM. B ELISA-based quantification of RAC1-GTP levels in control (−Dox) and BRAFV600E-expressing (+Dox) RPE-1 cells. Cells were measured at the indicated timepoints post thymidine release. RAC-1 GTP signal was measured using a colorimetric assay at 490 nM absorbance. N = 3 independent experiments. Unpaired Student’s t test. Error bars represent mean ± SEM. C Fold change (FC) in G1 RPE-1 FUCCI tetraploids following addition of RAC1 inhibitors. NSC2366 and EHT1864 were added coincident with BRAFV600E induction. Fold changes are expressed relative to control (+BRAFV600E, no drug) cells. N = 3 independent experiments. Unpaired Student’s t test. Error bars represent mean ± SEM. D DAPI and anti-RHOA staining in -BRAFV600E (−Dox) cells, BRAFV600E-expressing (+Dox) cells, and BRAFV600E- expressing (+Dox) RPE-1 cells treated with NSC2366 or EHT1864. Drugs were added coincident with Dox administration. Images are maximum intensity projections of z-stacks (0.20 µM). Scale bar = 7.5 µM. E Mean RHOA fluorescence intensity at the equator of control RPE-1 cells, BRAFV600E-expressing RPE-1 cells, and BRAFV600E-expressing RPE-1 cells treated with NSC2366 or EHT1864. Fluorescence intensities (mean gray values) of the equator were measured by sum intensity projections of z-stacks. N = 40 cells for −Dox, N = 38 for +Dox, N = 38 for +Dox +NSC2366, and N = 36 for +Dox +EHT1864. Brown- Forsythe and Welch one-way ANOVA with Dunnett’s multiple comparisons test. Error bars represent mean ± SEM.
    Rac1, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bk036+rac1/pm35840569-417-3-14?v=Cytoskeleton+Inc
    Average 96 stars, based on 1 article reviews
    rac1 - by Bioz Stars, 2026-07
    96/100 stars
      Buy from Supplier

    95
    Cytoskeleton Inc activation assay kits bk036
    Fig. 4 BRAFV600E acts during G1/S and activates <t>RAC1</t> to downregulate RhoA and generate tetraploid cells. A Fold change in G1 RPE-1 FUCCI tetraploids following inhibitor treatment. Fold changes are expressed relative to control (+BRAFV600E, no drug) samples. Inhibitors were added at indicated timepoints. N = 4 independent experiments. One-way ANOVA with Dunnett’s multiple comparisons test. Error bars represent mean ± SEM. B ELISA-based quantification of RAC1-GTP levels in control (−Dox) and BRAFV600E-expressing (+Dox) RPE-1 cells. Cells were measured at the indicated timepoints post thymidine release. RAC-1 GTP signal was measured using a colorimetric assay at 490 nM absorbance. N = 3 independent experiments. Unpaired Student’s t test. Error bars represent mean ± SEM. C Fold change (FC) in G1 RPE-1 FUCCI tetraploids following addition of RAC1 inhibitors. NSC2366 and EHT1864 were added coincident with BRAFV600E induction. Fold changes are expressed relative to control (+BRAFV600E, no drug) cells. N = 3 independent experiments. Unpaired Student’s t test. Error bars represent mean ± SEM. D DAPI and anti-RHOA staining in -BRAFV600E (−Dox) cells, BRAFV600E-expressing (+Dox) cells, and BRAFV600E- expressing (+Dox) RPE-1 cells treated with NSC2366 or EHT1864. Drugs were added coincident with Dox administration. Images are maximum intensity projections of z-stacks (0.20 µM). Scale bar = 7.5 µM. E Mean RHOA fluorescence intensity at the equator of control RPE-1 cells, BRAFV600E-expressing RPE-1 cells, and BRAFV600E-expressing RPE-1 cells treated with NSC2366 or EHT1864. Fluorescence intensities (mean gray values) of the equator were measured by sum intensity projections of z-stacks. N = 40 cells for −Dox, N = 38 for +Dox, N = 38 for +Dox +NSC2366, and N = 36 for +Dox +EHT1864. Brown- Forsythe and Welch one-way ANOVA with Dunnett’s multiple comparisons test. Error bars represent mean ± SEM.
    Activation Assay Kits Bk036, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/bk036+rac1/10__1091_slash_mbc__e10___08___0700-322-10-21?v=Cytoskeleton+Inc
    Average 95 stars, based on 1 article reviews
    activation assay kits bk036 - by Bioz Stars, 2026-07
    95/100 stars
      Buy from Supplier

    Image Search Results


    Journal: eLife

    Article Title: Paxillin facilitates timely neurite initiation on soft-substrate environments by interacting with the endocytic machinery

    doi: 10.7554/eLife.31101

    Figure Lengend Snippet:

    Article Snippet: peptide, recombinant protein , PAK-GST, GST-Photekin-RBD , Cytoskeleton Inc , Cytoskeleton Inc Cat. #BK035; Cat. # BK036 , .

    Techniques: Recombinant

    Fig. 4 BRAFV600E acts during G1/S and activates RAC1 to downregulate RhoA and generate tetraploid cells. A Fold change in G1 RPE-1 FUCCI tetraploids following inhibitor treatment. Fold changes are expressed relative to control (+BRAFV600E, no drug) samples. Inhibitors were added at indicated timepoints. N = 4 independent experiments. One-way ANOVA with Dunnett’s multiple comparisons test. Error bars represent mean ± SEM. B ELISA-based quantification of RAC1-GTP levels in control (−Dox) and BRAFV600E-expressing (+Dox) RPE-1 cells. Cells were measured at the indicated timepoints post thymidine release. RAC-1 GTP signal was measured using a colorimetric assay at 490 nM absorbance. N = 3 independent experiments. Unpaired Student’s t test. Error bars represent mean ± SEM. C Fold change (FC) in G1 RPE-1 FUCCI tetraploids following addition of RAC1 inhibitors. NSC2366 and EHT1864 were added coincident with BRAFV600E induction. Fold changes are expressed relative to control (+BRAFV600E, no drug) cells. N = 3 independent experiments. Unpaired Student’s t test. Error bars represent mean ± SEM. D DAPI and anti-RHOA staining in -BRAFV600E (−Dox) cells, BRAFV600E-expressing (+Dox) cells, and BRAFV600E- expressing (+Dox) RPE-1 cells treated with NSC2366 or EHT1864. Drugs were added coincident with Dox administration. Images are maximum intensity projections of z-stacks (0.20 µM). Scale bar = 7.5 µM. E Mean RHOA fluorescence intensity at the equator of control RPE-1 cells, BRAFV600E-expressing RPE-1 cells, and BRAFV600E-expressing RPE-1 cells treated with NSC2366 or EHT1864. Fluorescence intensities (mean gray values) of the equator were measured by sum intensity projections of z-stacks. N = 40 cells for −Dox, N = 38 for +Dox, N = 38 for +Dox +NSC2366, and N = 36 for +Dox +EHT1864. Brown- Forsythe and Welch one-way ANOVA with Dunnett’s multiple comparisons test. Error bars represent mean ± SEM.

    Journal: Nature communications

    Article Title: Oncogenic BRAF induces whole-genome doubling through suppression of cytokinesis.

    doi: 10.1038/s41467-022-31899-9

    Figure Lengend Snippet: Fig. 4 BRAFV600E acts during G1/S and activates RAC1 to downregulate RhoA and generate tetraploid cells. A Fold change in G1 RPE-1 FUCCI tetraploids following inhibitor treatment. Fold changes are expressed relative to control (+BRAFV600E, no drug) samples. Inhibitors were added at indicated timepoints. N = 4 independent experiments. One-way ANOVA with Dunnett’s multiple comparisons test. Error bars represent mean ± SEM. B ELISA-based quantification of RAC1-GTP levels in control (−Dox) and BRAFV600E-expressing (+Dox) RPE-1 cells. Cells were measured at the indicated timepoints post thymidine release. RAC-1 GTP signal was measured using a colorimetric assay at 490 nM absorbance. N = 3 independent experiments. Unpaired Student’s t test. Error bars represent mean ± SEM. C Fold change (FC) in G1 RPE-1 FUCCI tetraploids following addition of RAC1 inhibitors. NSC2366 and EHT1864 were added coincident with BRAFV600E induction. Fold changes are expressed relative to control (+BRAFV600E, no drug) cells. N = 3 independent experiments. Unpaired Student’s t test. Error bars represent mean ± SEM. D DAPI and anti-RHOA staining in -BRAFV600E (−Dox) cells, BRAFV600E-expressing (+Dox) cells, and BRAFV600E- expressing (+Dox) RPE-1 cells treated with NSC2366 or EHT1864. Drugs were added coincident with Dox administration. Images are maximum intensity projections of z-stacks (0.20 µM). Scale bar = 7.5 µM. E Mean RHOA fluorescence intensity at the equator of control RPE-1 cells, BRAFV600E-expressing RPE-1 cells, and BRAFV600E-expressing RPE-1 cells treated with NSC2366 or EHT1864. Fluorescence intensities (mean gray values) of the equator were measured by sum intensity projections of z-stacks. N = 40 cells for −Dox, N = 38 for +Dox, N = 38 for +Dox +NSC2366, and N = 36 for +Dox +EHT1864. Brown- Forsythe and Welch one-way ANOVA with Dunnett’s multiple comparisons test. Error bars represent mean ± SEM.

    Article Snippet: GTP-bound RhoA and Rac1 were immunoprecipitated from cells according to manufacturers’ protocols (BK-036, BK-128, Cytoskeleton).

    Techniques: Control, Enzyme-linked Immunosorbent Assay, Expressing, Colorimetric Assay, Staining, Fluorescence